Author: admin als-handoff

SEATTLE and VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that it has been added to the Russell 2000® Index, effective June…

CRL Cites Deficiencies at Third-Party Manufacturing Facility. No Efficacy or Clinical Safety Deficiencies Identified. SEATTLE and VANCOUVER, British Columbia, June 22, 2026 (GLOBE NEWSWIRE) —Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today…

Appointments Add Deep Biopharmaceutical Commercial Strategy, Clinical and Finance Expertise as Company Advances Toward Potential Cytisinicline Approval and Launch. SEATTLE and VANCOUVER, British Columbia, June 2, 2026 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (“Achieve” or the “Company”) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as…

ORCA-OL data complete the clinical evidence package supporting the cytisinicline smoking cessation NDA. No new safety signals identified by the independent Data Safety Monitoring Committee over 52 weeks of continuous exposure. Nausea — a common barrier to treatment adherence with smoking cessation therapies — was reported in only 2.5% of participants over 52 weeks of…

Christopher Martin joins the Board of Directors, with Mark Zappia and Jim Willis joining as Senior Vice President of Commercial and Vice President of Sales, reuniting the team behind the launch of Ohtuvayre®, one of the most successful specialty pharmaceutical launches in recent industry history. SEATTLE and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE)…